Among people carrying Val30Met (V30M), the most common cause of familial amyloid polyneuropathy (FAP), those experiencing symptoms have significantly higher blood levels of inflammation markers than those without signs of the rare inherited disease, a study showed. Symptomatic carriers were also found to have higher activity of neutrophils, a…

Familial amyloid neuropathy (FAP) caused by a mutation in the TTR gene called Ala97Ser is associated with a later onset of symptoms, which most commonly involve numbness in the feet or hands. That’s according to new data from 21 Ala97Ser-associated FAP cases in mainland China, compiled in the largest…

It’s been nearly a month since the charity I lead, the New Zealand Amyloidosis Patients Association (NZAPA), held a conference for patients and caregivers. The two-day event was made possible by the active participation of those living with various types of amyloidosis, including hereditary ATTR (hATTR), wild-type, and AL…

A specialized MRI technique known as the variable echo time (vTE) sequence may help identify structural changes in nerves linked to damage in individuals with familial amyloid polyneuropathy (FAP), according to a recent study. Additionally, a parameter of the vTE MRI sequence called short T2-weighted imaging was identified as…

The European Commission has expanded the indication of Amvuttra (vutrisiran) to include adults with ATTR amyloidosis with cardiomyopathy, or heart damage (ATTR-CM), regardless of whether they carry disease-causing mutations. “Estimates show approximately 100,000 people are affected by ATTR amyloidosis across Europe, most with cardiomyopathy, so this approval marks a…